Yam  Nath Paudel
Yam Nath Paudel
Verified email at monash.edu
Title
Cited by
Cited by
Year
HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction
YN Paudel, M Shaikh, A Chakraborti, Y Kumari, Á Aledo-Serrano, ...
Frontiers in neuroscience 12, 628, 2018
572018
Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling
YN Paudel, E Angelopoulou, C Piperi, VRMT Balasubramaniam, ...
European journal of pharmacology 858, 172487, 2019
372019
Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy
YN Paudel, MF Shaikh, S Shah, Y Kumari, I Othman
European journal of pharmacology 837, 145-155, 2018
342018
High mobility group box 1 (HMGB 1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches
YN Paudel, BD Semple, NC Jones, I Othman, MF Shaikh
Journal of neurochemistry 151 (5), 542-557, 2019
222019
Embelin prevents seizure and associated cognitive impairments in a pentylenetetrazole-induced kindling zebrafish model
UP Kundap, YN Paudel, Y Kumari, I Othman, M Shaikh
Frontiers in pharmacology 10, 315, 2019
142019
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
YN Paudel, E Angelopoulou, C Piperi, I Othman, K Aamir, M Shaikh
Cells 9 (2), 383, 2020
102020
2-[(4-Chlorobenzyl) amino]-4-methyl-1, 3-thiazole-5-carboxylic acid exhibits antidiabetic potential and raises insulin sensitivity via amelioration of oxidative enzymes and …
YN Paudel, MR Ali, S Shah, M Adil, MS Akhtar, R Wadhwa, S Bawa, ...
Biomedicine & Pharmacotherapy 89, 651-659, 2017
102017
Emerging neuroprotective effect of metformin in Parkinson’s disease: A molecular crosstalk
YN Paudel, E Angelopoulou, C Piperi, MF Shaikh, I Othman
Pharmacological Research 152, 104593, 2020
82020
Potential neuroprotective effect of the HMGB1 inhibitor Glycyrrhizin in neurological disorders
YN Paudel, E Angelopoulou, B Semple, C Piperi, I Othman, MF Shaikh
ACS Chemical Neuroscience 11 (4), 485-500, 2020
52020
High mobility group box 1 (HMGB1) protein in Multiple Sclerosis (MS): Mechanisms and therapeutic potential
YN Paudel, E Angelopoulou, KC Bhuvan, C Piperi, I Othman
Life sciences 238, 116924, 2019
52019
Hepatoprotective and antioxidant effects of fish oil on isoniazid-rifampin induced hepatotoxicity in rats
AS Basheer, A Siddiqui, YN Paudel, MQ Hassan, M Imran, AK Najmi, ...
PharmaNutrition 5 (1), 29-33, 2017
52017
Flotillin: A Promising Biomarker for Alzheimer’s Disease
E Angelopoulou, YN Paudel, M Shaikh, C Piperi
Journal of Personalized Medicine 10 (2), 20, 2020
42020
Pilocarpine Induced Behavioral and Biochemical Alterations in Chronic Seizure-Like Condition in Adult Zebrafish
YN Paudel, Y Kumari, SAZ Abidin, I Othman, M Shaikh
International journal of molecular sciences 21 (7), 2492, 2020
42020
Envisioning the neuroprotective effect of metformin in experimental epilepsy: a portrait of molecular crosstalk
HS Nandini, YN Paudel, KL Krishna
Life sciences 233, 116686, 2019
42019
Guggulsterone, a farnesoid X receptor antagonist lowers plasma trimethylamine-N-oxide levels: An evidence from in vitro and in vivo studies
A Gautam, YN Paudel, SAZ Abidin, U Bhandari
Human & experimental toxicology 38 (3), 356-370, 2019
42019
“2-(4-Fluorobenzamido)-4-methylthiazole-5-carboxylic acid” a novel thiazole compound, ameliorates insulin sensitivity and hyperlipidaemia in streptozotocin-induced diabetic …
YN Paudel, MR Ali, M Adil, S Bawa, M Sharma
Biomedicine & Pharmacotherapy 95, 1232-1241, 2017
42017
Implication of HMGB1 signaling pathways in Amyotrophic lateral sclerosis (ALS): From molecular mechanisms to pre-clinical results
YN Paudel, E Angelopoulou, C Piperi, I Othman, MF Shaikh
Pharmacological Research, 104792, 2020
32020
Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington’s disease
E Angelopoulou, YN Paudel, C Piperi
Journal of Molecular Medicine, 1-10, 2020
32020
miR-124 and Parkinson’s disease: A biomarker with therapeutic potential
E Angelopoulou, YN Paudel, C Piperi
Pharmacological research 150, 104515, 2019
32019
EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice
S Shah, MS Akhtar, MQ Hassan, M Akhtar, YN Paudel, AK Najmi
Life sciences 210, 29-39, 2018
32018
The system can't perform the operation now. Try again later.
Articles 1–20